To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: Raloxifene Reduces Risk of Invasive Estrogen Receptor-Positive Breast Cancer
URL: http://www.pslgroup.com/dg/223592.htm
Doctor's Guide
June 10, 2008

BETHESDA, Md -- June 10, 2008 -- Women who took raloxifene were less likely to develop invasive estrogen receptor (ER)-positive breast cancer compared with women who did not, according to data from a randomised controlled trial published online today in the Journal of the National Cancer Institute. However, the drug did not reduce the risk of noninvasive cancer or invasive ER-negative cancers.

A previous analysis of data from the Raloxifene Use for the Heart (RUTH) trial, which enrolled women with coronary heart disease or those at an increased risk for the disease, showed that the drug did not protect against heart disease, which was one of the primary aims of the trial. But after a median follow up of 5.6 years, it did reduce the risk of invasive breast cancer by 44% compared with women not taking the drug.

To investigate the specific types and stages of breast cancer affected by raloxifene, as well as the timing of its action and the types of patients it can help, Deborah Grady, MD, University of California at San Francisco, San Francisco, California, and colleagues examined the RUTH trial data in more detail.

The 5,044 women who took raloxifene had a 55% reduction in the risk of developing invasive ER-positive breast cancer compared with the 5,057 women who took placebo. That is equivalent to an absolute reduction in risk of 1.2 cases per 1,000 women treated for 1 year. There was no reduction in the risk of invasive ER-negative breast cancer or in noninvasive breast cancers of any type. The researchers saw the same effects regardless of the women's age, prior hormone use, or baseline risk of breast cancer.

The reduction in breast cancer risk is consistent with findings from other trials that involved women without heart disease. Women who took raloxifene in the RUTH trial had an increased incidence of blood clots and fatal strokes compared with those who took placebo. Thus, the researchers conclude that women who are considering taking raloxifene need to weigh the risks and benefits. "Assuming that the relative risks from the RUTH trial apply to women in the general population, the best benefit-to-risk ratio would occur in women at high risk of breast cancer and osteoporosis and low risk of venous thrombosis and stroke," the authors wrote.


SOURCE: Journal of the National Cancer Institute

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.